Asymmetric IgG Antibodies Induced by Different Immunotherapies in a Murine Model of Allergy

REFERENCES

• Akdis M., Blaser K., Akdis C. A. T regulatory cells in allergy. Chem Immunol Allergy 2006; 91: 159–173
   PubMedGoogle Scholar
• Apicella C., Custidiano A., Miranda S., Novoa L., Dokmetjian J., Gentile T. Differential macrophage modulation of asymmetric IgG antibody synthesis by soluble or particulate stimuli. Immunol Lett 2006; 103(2)177–185
   PubMedGoogle Scholar
• Batanero E., Barral P., Villalba M., Rodriguez R. Biodegradable poly (DL-lactide glycolide) microparticles as a vehicle for allergen-specific vaccines: a study performed with Ole e 1, the main allergen of olive pollen. J Immunol Meth 2002; 259(1–2)87–94
   PubMedGoogle Scholar
• Batanero E., Barral P., Villalba M., Rodriguez R. Encapsulation of Ole e 1 in biodegradable microparticles induces Th1 response in mice: a potential vaccine for allergy. J Control Release 2003; 92(3)395–398
   PubMed Web of Science ®Google Scholar
• Bousquet J., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Allergy Clin Immunol Oct, 1998; 102(4 Pt 1)558–562, Review
   Google Scholar
• Canellada A., Färber A., Zenclussen A. C., et al. Interleukin regulation of asymmetric antibody synthesized by isolated placental B cells. Am J Reprod Immunol 2002; 48(4)275–282
   PubMedGoogle Scholar
• Carcaboso A. M., Hernández R. M., Igartua M., Rosas J. E., Patarroyo M. E., Pedraz J. L. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004; 22(11–12)1423–1432
   PubMed Web of Science ®Google Scholar
• Chen L. J., Chiang C. H., Yeh M. K. The mechanism of PLA microparticle formation by water-in-oil-in-water solvent evaporation method. J Microencapsul 2002; 19(3)333–346
   PubMed Web of Science ®Google Scholar
• Ciprandi G., Marseglia G. L., Tosca M. A. Allergen-specific immunotherapy: an update on immunological mechanisms of action. Monaldi Arch Chest Dis 2006; 65(1)34–37
   PubMedGoogle Scholar
• Coombes A. G., Meikle M. Resorbable synthetic polymers as replacements for bone graft. Clin Mater 1994; 17(1)35–67
   PubMedGoogle Scholar
• Daeron M., Malbec O., Latour S., Arock M., Friedman W. H. Regulation of high-affinity IgE receptor mediated mast cell activation by murine low affinity IgG receptors. J Clin Invest 1995; 95: 577–585
   PubMedGoogle Scholar
• Dearman R. J., Skinner R. A., Deakin N., Shaw D., Kimber I. Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukaemia (RBL). Cell Assay Toxicol 2005; 206(2)195–205
   Google Scholar
• Dearman R. J., Skinner R. A., Herouet C., Labay K., Debruyne E., Kimber I. Induction of IgE antibody responses by protein allergens: inter-laboratory comparisons. Food Chem Toxicol 2003; 41(11)1509–1516
   PubMed Web of Science ®Google Scholar
• Durham S. R., Walker S. M., Varga E. M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 12 1999; 341(7)468–475
   PubMed Web of Science ®Google Scholar
• Ejrnaes A. M., Bodtger U., Larsen J. N., Svenson M. The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses. Mol Immunol 2004; 41(5)471–478
   PubMedGoogle Scholar
• Finkelman F. D., Rothenberg M. E., Brandt E. B., Morris S. C., Strait R. T. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol 2005; 115(3)449–457
   PubMedGoogle Scholar
• Gehlhar K., Schlaak M., Becker W., Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29(4)497–506
   PubMedGoogle Scholar
• Gentile T., Malan Borel I., Angelucci J., Miranda S., Margni R. Preferential synthesis of asymmetric antibodies in rats immunized with paternal particulate antigen. Effect on pregnancy. J Reprod Immunol 1994; 22: 173–183
   Google Scholar
• Guerin V., Dubarryr M., Robic D., et al. Microsphere entrapped bee-venom phospholipase A2 retains specific IgE binding capacity: a possible use for oral specific immunotherapy. J Microencapsul Nov–Dec, 2002; 19(6)761–765
   PubMed Web of Science ®Google Scholar
• Hayglass K. T., Stefura B. P. Anti-interferon gamma treatment blocks the ability of glutaraldehyde-polymerized allergens to inhibit specific IgE responses. J Exp Med 1991; 173(2)279–285
   PubMedGoogle Scholar
• Igartua M., Hernandez R. M., Gutierro I., Gascon A. R., Pedraz J. L. Preliminary assessment of the immune response to Olea europaea pollen extracts encapsulated into PLGA microspheres. Pharm Dev Technol 2001; 6(4)621–627
   PubMed Web of Science ®Google Scholar
• Jarolim E., Poulsen L. K., Stadler B. M., et al. A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol 1990; 85(6)996–1004
   PubMedGoogle Scholar
• Johansen P., Men Y., Merkle H. P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000; 50(1)129–146
   PubMed Web of Science ®Google Scholar
• Nouri-Aria K. T., Wachholz P. A., Francis J. N., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172(5)3252–3259
   PubMed Web of Science ®Google Scholar
• Labeta M., Margni R. A., Leoni J., Binaghi R. Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 1986; 57(2)311–317
   PubMed Web of Science ®Google Scholar
• Leibiger H., Hansen A., Shoenherr G., et al. Glycosylation analysis of polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma. Mol Immunol 1995; 32(8)595–602
   PubMedGoogle Scholar
• Leoni J., Labeta M., Margni R. A. The asymmetric IgG non-precipitating antibody. Localization of the oligosaccharide involved, by concanavalin A interaction. Mol Immunol 1986; 23(12)1397–1400
   PubMedGoogle Scholar
• Malan Borel I., Gentile T., Angelucci J., Binaghi R., Margni R. Asymmetrically glycosylated IgG isolated from non-immune human sera. Biochim Biophys Acta 1989; 990: 162–164
   PubMedGoogle Scholar
• Malling H. J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 5: 461–472
   Google Scholar
• Margni R. A., Binaghi R. Purification and properties of non precipitating rabbit antibodies. Immunology 1972; 22(4)557–563
   PubMedGoogle Scholar
• Margni R. A., Gentile T., Miranda S. The antigen protective arm in a Th2-regulated immune response. Inmunología 2002; 21: 29–35, (Barcelona)
   Google Scholar
• Margni R. A, Hajos S. Biological and physicochemical properties of purified anti-DNP guinea pig non-precipitating antibodies. Immunology 1973; 24(3)435–443
   PubMedGoogle Scholar
• Margni R. A, Malan Borel I. Paradoxical behavior of asymmetric IgG antibodies. Immunol Rev 1998; 163: 77–87
   PubMedGoogle Scholar
• Margni R. A, Parma A, Cerone S., Erpelding A., Perdigón G. Agglutinating and non agglutination antibodies in rabbits inoculated with a particulate antigen (Salmonella thypimurium). Immunology 1983; 48(2)351–359
   PubMedGoogle Scholar
• Margni R. A., Perdigón G., Gentile T., Abatángelo C., Dokmetjian J. IgG precipitating and co-precipitating antibodies in rabbits repeatedly injected with soluble and particulate antigens. Vet Immunol Immunopathol 1986; 13(1–2)51–61
   PubMedGoogle Scholar
• Miranda S., Canellada A., Gentile T., Margni R. Interleukin-6 and dexamethasone modulate in vitro asymmetric antibody synthesis and UDP-Glc glycoprotein glycosyltransferase activity. J Reprod Immunol 2005; 66: 141–150
   PubMedGoogle Scholar
• Morelli L., Plotkin L., Leoni J., Fossati C. A., Margni R. A. Analysis of oligosaccharides involved in the asymmetrical glycosylation of IgG monoclonal antibodies. Mol Immunol 1993; 30(7)695–700
   PubMedGoogle Scholar
• Parma A. E., Cerone S., Erpelding A., Margni R. A. Immune response in rabbits inoculated with Salmonella typhimurium. Rev Arg Microbiol 1980; 12(3)100–104
   PubMedGoogle Scholar
• Postlethwait R. W., Smith B. M. A new synthetic absorbable suture. Surg Gynecol Obstet 1975; 140(3)377–380
   PubMedGoogle Scholar
• Roth-Walter F., Schöll I., Untersmayr E., et al. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 2005; 23(21)2703–2710
   PubMed Web of Science ®Google Scholar
• Scholl I., Boltz-Nitulescu G., Jensen-Jarolim E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Cntrl Rel 2005; 104(1)1–27
   PubMedGoogle Scholar
• Scholl I., Weissenbock A., Forster-Waldl E., et al. Allergen-loaded biodegradable poly (D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004; 34(2)315–321
   PubMed Web of Science ®Google Scholar
• Investigation of the Structural and Immunologic Integrity of an Allergen Entrapped in Poly(Lactide-Co-Glycolide) Microparticles, S. Sharif, A. Wheeler, D. T. C. R. O'Hagan, Society. Deerfield, Nice, France 1994; 292–295
   Google Scholar
• Storni T., Kundig T. M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005; 57(3)333–355
   PubMed Web of Science ®Google Scholar
• Strait R., Morris S., Finkelman F. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking. J Clin Invest 2006; 116(3)833–841
   PubMed Web of Science ®Google Scholar
• Vila Jato J. L. Aspectos fundamentales de los sistemas farmacéuticos y operaciones básicas. Tecnología Farmacéutica. Editorial Síntesis, Madrid 1997; 75–142
   Google Scholar
• Wachholz P. A., Durham S. R. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4(4)313–318, Review
   PubMed Web of Science ®Google Scholar
• Wise D. L., Trantolo D. J., Marino R. T. Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial and vaccines. Adv Drug Deliv Rev 1987; 1: 19–39
   Google Scholar